SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Myocardial infarction (MI) is the irreversible death of cardiomyocyte secondary to prolonged
lack of oxygen or fresh blood supply. Historically considered as merely cardiomyocyte …

Importance The diuretic effect of sodium-glucose cotransporter 2 inhibitors may result in
interaction with background diuretic therapy in patients with heart failure and preserved …

Acute kidney injury and chronic kidney disease are among the most common non-
communicable diseases in the developed world, with increasing prevalence. Patients with …

For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity
to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to …

As the prevalence of diabetic kidney disease (DKD) continues to rise, so does the need for a
novel therapeutic modality that can control and slow its progression to end-stage renal …

Several recent randomized controlled trials (RCTs) have demonstrated the wide clinical
application of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in improving kidney and …

Abstract Background and Aims To investigate the cardiovascular effects of sodium–glucose
co-transporter-2 inhibitors (SGLT2i) with concomitant mineralocorticoid receptor antagonist …

Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering
agents that provide cardiovascular and renal protection in both patients with and without …

As the tide of obesity and its complications are on the rise, there is an urgent need for new
drugs with weight‑lowering and beneficial metabolic properties. Obesity‑related disorders …